reference/36211077

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36211077

Outgoing Links

Predicate	Object
contentType	Randomized Controlled Trial\|Clinical Trial, Phase II\|Journal Article
endingPage	84
issn	0967-5868
pageRange	76-84
publicationName	Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
startingPage	76
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_111f1b6e0633f44904ff6b8dcef97de6 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c1469633fe4fd0be5fad8c227c38c5a1
bibliographicCitation	GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espié P, Dupuy C, Hartmann N, Pezous N, Kinhikar A, Tichy M, Dionne A, Vissing J, Andersen H, Schoser B, Meisel A, Jordan B, Devlikamova F, Poverennova I, Stuchevskaya F, Lin T, Rush JS, Gergely P. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. Journal of Clinical Neuroscience. 2024 Jan;119():76–84. doi: 10.1016/j.jocn.2023.11.013.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a84d564f5b472e87394b292fca0f77fb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e6ee7b0c136ae323152ef259f742744 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1df12d3813dd2fe1ee6723aadde7063 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38e44f52c1894e7f43baf0a951034a25 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1cb9926a27f292e6358d2f3d88fc080 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b11030696ef402d7acd9ed7b7c1ce4c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bb9fb6f848864e10a491b8e737dde1f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c8085d2dee9831ae6df41d76655a65d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42611565b79ecfde2a71bcfa569e0f8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0af4070f32c2711098c9b57d998e1d6c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a73d7041a3c2e5f35eda1296009183b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f11897fc99bf9b15cfc7f86ec80b9b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e5228ba5dee95447b23b5e184f2b4b2f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_29a61980edc1027eca8ae53de84c1da4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04096eda77d4ebfde745145ad470d878 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de2b5be1bec5ea9a3add043739f1963d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f71c95a89008d7b723c898c2e4dd7c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_afbfeaadd6ea03378620aa5b6862e99d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b1f7db8f58b3cef83d22f24f311a88e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b32872d73dcbf06c1e08fe60118a6bf3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6381dfd197b79efdfca10c8b007f8f2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74c626365d9a532134ff701b41266592
date	202401
identifier	https://doi.org/10.1016/j.jocn.2023.11.013 https://pubmed.ncbi.nlm.nih.gov/37988976
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21730 https://portal.issn.org/resource/ISSN/0967-5868
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
discusses	http://id.nlm.nih.gov/mesh/M000654537 http://id.nlm.nih.gov/mesh/M0001357
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009157Q000188 http://id.nlm.nih.gov/mesh/D009157Q000139 http://id.nlm.nih.gov/mesh/D000203
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004311

Showing number of triples: 1 to 49 of 49.